Most patients at the 4 and 7μg dose developed anti-drug-antibodies (ADA) after the 4th catumaxomab infusion, and the occurrence of ADA coincided with a significant improvement of the observed hepatitis. Here, ADA is linked to hepatitis A virus infection.